Molgramostim Inhalation Solution

Name: Molgramostim Inhalation Solution in Autoimmune pulmonary alveolar proteinosis: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

Autoimmune pulmonary alveolar proteinosis

Manufacturer: Savara
Regulatory submission: BLA resubmitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

4 evidence topics · 3 sources

Sponsor and generic name

“Sponsor: Savara Inc.” (opens the source at this quote in a new tab)
“Generic Name: recombinant human GM-CSF, molgramostim” (opens the source at this quote in a new tab)

Manufacturer: Savara

“Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)” (opens the source at this quote in a new tab)

Proposed trade name and product name

“MOLBREEVI” (opens the source at this quote in a new tab)
“molgramostim inhalation solution” (opens the source at this quote in a new tab)

Therapeutic class

“inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF)” (opens the source at this quote in a new tab)